NCT06714123View on ClinicalTrials.gov

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Pulmonary Fibrosis, Interstitial Lung DiseaseIdiopathic Pulmonary Fibrosis
Interventions
DRUG

Senicapoc

administering 30 mg senicapoc a day, in addition to standard of care.

DRUG

Placebo

Tablets similar in size and color

Trial Locations (3)

5000

NOT_YET_RECRUITING

Odense University Hospital, Odense C

8200

RECRUITING

Aarhus University Hospital, Aarhus N

50406

NOT_YET_RECRUITING

Tartu University Hospital,, Tartu

All Listed Sponsors
collaborator

Odense Patient Data Explorative Network

OTHER

lead

Vejle Hospital

OTHER

NCT06714123 - Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease | Biotech Hunter | Biotech Hunter